LD50=597.0 mg/kg (Orally in rats)
One of the adrenergic beta-antagonists used as an antihypertensive, anti-anginal, and anti-arrhythmic agent. Alprenolol is no longer marketed by AstraZeneca, but may still be available in generic varieties.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Ceritinib | Alprenolol may increase the bradycardic activities of Ceritinib. |
| Ivabradine | Alprenolol may increase the bradycardic activities of Ivabradine. |
| Ruxolitinib | Ruxolitinib may increase the bradycardic activities of Alprenolol. |
| Alfuzosin | Alfuzosin may increase the hypotensive activities of Alprenolol. |
| Amifostine | Alprenolol may increase the hypotensive activities of Amifostine. |
| Diazoxide | Diazoxide may increase the hypotensive activities of Alprenolol. |
| Methylphenidate | Methylphenidate may decrease the antihypertensive activities of Alprenolol. |
| Dexmethylphenidate | Dexmethylphenidate may decrease the antihypertensive activities of Alprenolol. |
| Obinutuzumab | Alprenolol may increase the hypotensive activities of Obinutuzumab. |
| Pentoxifylline | Pentoxifylline may increase the hypotensive activities of Alprenolol. |
| Rituximab | Alprenolol may increase the hypotensive activities of Rituximab. |
| Desmopressin | Desmopressin may decrease the antihypertensive activities of Alprenolol. |
| Doxapram | Doxapram may decrease the antihypertensive activities of Alprenolol. |
| Phenmetrazine | Phenmetrazine may decrease the antihypertensive activities of Alprenolol. |
| Dopamine | Dopamine may decrease the antihypertensive activities of Alprenolol. |
| Dutasteride | Dutasteride may decrease the antihypertensive activities of Alprenolol. |
| Finasteride | Finasteride may decrease the antihypertensive activities of Alprenolol. |
| Epicaptopril | Epicaptopril may decrease the antihypertensive activities of Alprenolol. |
| 1-benzylimidazole | 1-benzylimidazole may decrease the antihypertensive activities of Alprenolol. |
| Tyramine | Tyramine may decrease the antihypertensive activities of Alprenolol. |
| Moxisylyte | Moxisylyte may decrease the antihypertensive activities of Alprenolol. |
| Atipamezole | Atipamezole may decrease the antihypertensive activities of Alprenolol. |
| Siponimod | Siponimod may decrease the antihypertensive activities of Alprenolol. |
| Idazoxan | Idazoxan may decrease the antihypertensive activities of Alprenolol. |
| Tramazoline | Tramazoline may decrease the antihypertensive activities of Alprenolol. |
| Fenozolone | Fenozolone may decrease the antihypertensive activities of Alprenolol. |
| Xenon | Xenon may decrease the antihypertensive activities of Alprenolol. |
| Buflomedil | Buflomedil may decrease the antihypertensive activities of Alprenolol. |
| Mefenorex | Mefenorex may decrease the antihypertensive activities of Alprenolol. |
| Quinoline Yellow WS | Quinoline Yellow WS may decrease the antihypertensive activities of Alprenolol. |
| Selpercatinib | Selpercatinib may decrease the antihypertensive activities of Alprenolol. |
| Naxitamab | Naxitamab may decrease the antihypertensive activities of Alprenolol. |
| Buprenorphine | Alprenolol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Alprenolol. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Alprenolol. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Alprenolol. |
| Hydrocodone | Alprenolol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Alprenolol. |
| Magnesium sulfate | The therapeutic efficacy of Alprenolol can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Alprenolol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Alprenolol may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Alprenolol. |
| Mirtazapine | Alprenolol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Alprenolol. |
| Orphenadrine | Alprenolol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Alprenolol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Alprenolol. |
| Pramipexole | Alprenolol may increase the sedative activities of Pramipexole. |
| Ropinirole | Alprenolol may increase the sedative activities of Ropinirole. |
| Rotigotine | Alprenolol may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Alprenolol. |
| Sodium oxybate | Alprenolol may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Alprenolol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Alprenolol. |
| Thalidomide | Alprenolol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Alprenolol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Amiodarone | The therapeutic efficacy of Alprenolol can be increased when used in combination with Amiodarone. |
| Bupivacaine | The serum concentration of Bupivacaine can be increased when it is combined with Alprenolol. |
| Dipyridamole | Dipyridamole may increase the bradycardic activities of Alprenolol. |
| Disopyramide | Disopyramide may increase the bradycardic activities of Alprenolol. |
| Dronedarone | Dronedarone may increase the bradycardic activities of Alprenolol. |
| Fingolimod | Alprenolol may increase the bradycardic activities of Fingolimod. |
| Floctafenine | The risk or severity of adverse effects can be increased when Alprenolol is combined with Floctafenine. |
| Mepivacaine | The serum concentration of Mepivacaine can be increased when it is combined with Alprenolol. |
| Methacholine | Alprenolol may increase the bronchoconstrictory activities of Methacholine. |
| Midodrine | The therapeutic efficacy of Midodrine can be decreased when used in combination with Alprenolol. |
| Nifedipine | The risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Alprenolol. |
| Propafenone | The risk or severity of adverse effects can be increased when Propafenone is combined with Alprenolol. |
| Regorafenib | Regorafenib may increase the bradycardic activities of Alprenolol. |
| Reserpine | Reserpine may increase the hypotensive activities of Alprenolol. |
| Deserpidine | Deserpidine may increase the hypotensive activities of Alprenolol. |
| Guanethidine | Guanethidine may increase the hypotensive activities of Alprenolol. |
| Rivastigmine | Alprenolol may increase the bradycardic activities of Rivastigmine. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Alprenolol. |
| Dicoumarol | The risk or severity of adverse effects can be increased when Alprenolol is combined with Dicoumarol. |
| Phenindione | The risk or severity of adverse effects can be increased when Alprenolol is combined with Phenindione. |
| Warfarin | The risk or severity of adverse effects can be increased when Alprenolol is combined with Warfarin. |
| Phenprocoumon | The risk or severity of adverse effects can be increased when Alprenolol is combined with Phenprocoumon. |
| Acenocoumarol | The risk or severity of adverse effects can be increased when Alprenolol is combined with Acenocoumarol. |
| 4-hydroxycoumarin | The risk or severity of adverse effects can be increased when Alprenolol is combined with 4-hydroxycoumarin. |
| Coumarin | The risk or severity of adverse effects can be increased when Alprenolol is combined with Coumarin. |
| (R)-warfarin | The risk or severity of adverse effects can be increased when Alprenolol is combined with (R)-warfarin. |
| Ethyl biscoumacetate | The risk or severity of adverse effects can be increased when Alprenolol is combined with Ethyl biscoumacetate. |
| Fluindione | The risk or severity of adverse effects can be increased when Alprenolol is combined with Fluindione. |
| Clorindione | The risk or severity of adverse effects can be increased when Alprenolol is combined with Clorindione. |
| Diphenadione | The risk or severity of adverse effects can be increased when Alprenolol is combined with Diphenadione. |
| Tioclomarol | The risk or severity of adverse effects can be increased when Alprenolol is combined with Tioclomarol. |
| (S)-Warfarin | The risk or severity of adverse effects can be increased when Alprenolol is combined with (S)-Warfarin. |
| Mirabegron | The serum concentration of Alprenolol can be increased when it is combined with Mirabegron. |
| Molsidomine | Molsidomine may increase the hypotensive activities of Alprenolol. |
| Insulin argine | Alprenolol may increase the hypoglycemic activities of Insulin argine. |
| Remikiren | Remikiren may increase the hypotensive activities of Alprenolol. |
| Guanadrel | Guanadrel may increase the hypotensive activities of Alprenolol. |
| Bosentan | Bosentan may increase the hypotensive activities of Alprenolol. |
| Candoxatril | Candoxatril may increase the hypotensive activities of Alprenolol. |
| Cryptenamine | Cryptenamine may increase the hypotensive activities of Alprenolol. |
| Dorzolamide | Alprenolol may increase the hypotensive activities of Dorzolamide. |
| Bimatoprost | Alprenolol may increase the hypotensive activities of Bimatoprost. |
| Pentolinium | Alprenolol may increase the hypotensive activities of Pentolinium. |
| Trimethaphan | Alprenolol may increase the hypotensive activities of Trimethaphan. |